IP Library Granted Patent US 12667542
Granted Patent B2
US 12667542 · App. 17/711,528 · Granted Jun 30, 2026

Substance delivery carrier and composition

Inventors: Mitsuko Ishihara (Setagaya, JP); Shigehisa Kawata (Niiza, JP); Susumu Goyama (Bunkyo, JP)
Assignees: KABUSHIKI KAISHA TOSHIBA; The University of Tokyo
A61K9/127A61K45/06A61K47/20A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667542
App. No.
17/711,528
Granted
Jun 30, 2026
Kind
B2
Abstract

According to one embodiment, a substance delivery carrier and a composition are used for delivering an intended substance to a myeloid tumor cell. The substance delivery carrier has a lipid particle, and an intended substance encapsulated in the lipid particle. The lipid particle contains, as a constituent thereof, at least a first lipid represented by formula (I).

Claims (34)

1 . A method for delivering a substance to a myeloid tumor cell, the method comprising:

preparing a substance delivery carrier which comprises a lipid particle and the substance encapsulated in the lipid particle; and

contacting the substance delivery carrier with the myeloid tumor cell;

wherein the lipid particle contains a first lipid represented by formula (I):

and at least one of cationic lipid, neutral lipid, anti-aggregation lipid, and cholesterol,

wherein

a mole ratio of the first lipid in a lipid composition of the lipid particle is from 10% to 50%, and

the lipid particle exhibits 8.4 pKa or smaller, in an environment with an ionic strength of 3.599×10 −3 mol/dm 3 .

2 . The method of claim 1 , wherein the substance contains siRNA that suppresses expression of a gene relevant to onset and progression of the myeloid tumor cell.

3 . The method of claim 2 , wherein the siRNA contains a sequence complementary to a part of the gene.

4 . The method of claim 2 , wherein the gene is at least one selected from the group consisting of transcription factor, fusion gene, epigenome control factor, phosphorylating enzyme-related gene, immunosuppressive factor, a ubiquitin-related factor, apoptosis control factor, and non-coding RNA.

5 . The method of claim 2 , wherein the gene is at least one selected from RUNX1, RUNX2, MECOM, MYB, MYC, HOXA9, MEIS1, HHEX, and ERG.

6 . The method of claim 1 , wherein the lipid particle further encapsulates at least either a pH adjustor or an osmoregulator.

7 . The method of claim 1 , wherein

the myeloid tumor cell exists in vivo in a subject, and

contacting is carried out by administering a composition that contains the substance delivery carrier to the subject.

8 . A substance delivery carrier for delivering a substance to a myeloid tumor cell, the substance delivery carrier comprising:

a lipid particle; and

the substance encapsulated in the lipid particle,

the lipid particle containing at least a first lipid represented by formula (I):

and at least one of cationic lipid, neutral lipid, anti-aggregation lipid, and cholesterol

wherein

a mole ratio of the first lipid in a lipid composition of the lipid particle is from 10% to 50%, and

the lipid particle exhibits 8.4 pKa or smaller, in an environment with an ionic strength of 3.599×10−3 mol/dm3.

9 . The substance delivery carrier of claim 8 , wherein the lipid particle is weakly cationic.

10 . The substance delivery carrier of claim 8 , wherein the substance contains siRNA that suppresses expression of a gene relevant to onset and progression of the myeloid tumor cell.

11 . The substance delivery carrier of claim 10 , wherein the siRNA contains a sequence complementary to a part of the gene.

12 . The substance delivery carrier of claim 10 , wherein the gene is at least one selected from the group consisting of transcription factor, fusion gene, epigenome control factor, phosphorylating enzyme-related gene, immunosuppressive factor, a ubiquitin-related factor, apoptosis control factor, and non-coding RNA.

13 . The substance delivery carrier of claim 10 , wherein

the gene is at least one selected from RUNX1, RUNX2, MECOM, MYB, MYC, HOXA9, MEIS1, HHEX, and ERG.

14 . The substance delivery carrier of claim 8 , wherein the lipid particle further encapsulates at least either pH adjustor or an osmoregulator.

15 . A composition comprising the substance delivery carrier of claim 8 ,

and further comprising at least either a carrier or a storage protectant.

16 . The composition of claim 15 , wherein the storage protectant is present and is dimethylsulfoxide.